FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:1540-1541 May 26, 1994 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Fludarabine monophosphate is a synthetic purine antimetabolite that has been used almost exclusively in the treatment of chronic lymphoid cancers¹. The medication may cause dose-related myelosuppression. Recently, CD4+ T-lymphocytopenia with associated opportunistic infections has been observed in a small number of patients treated with this agent². CD4+ T lymphocytes are believed to have a pivotal role in the pathogenesis of psoriasis³. We describe a patient with B-cell chronic lymphocytic leukemia and chronic plaque psoriasis whose skin condition remitted during fludarabine monophosphate therapy.

A 67-year-old man with a 10-year history of B-cell chronic lymphocytic leukemia . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Viallard, J-F, Mercie, P, Faure, I, Pellegrin, J-L, Leng, B (1999). Successful treatment of lupus with fludarabine. Lupus 8: 767-769 [Abstract]  
• Roth, L J, Pugh, E J (1999). The role of endoscopic biliary stents in palliative care. Palliat Med 13: 63-68 [Abstract]  
• Quigley, C., Plowman, P.N. (1996). 5NT 3 receptor antagonists and pruritus due to cholestasis. Palliat Med 10: 54-54  
• Lee, Y.-M., Kaplan, M. M. (1995). Primary Sclerosing Cholangitis. NEJM 332: 924-933 [Full Text]